← back to search

Guillaume Bouguen

Inserm · FR
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Autoimmune and Inflammatory Disorders, and Anorectal Disease Treatments and Outcomes.
h-index
46
citations
9,097
works
366
NIH funding
primary concept
email

Recent publications

Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <scp>GETAID</scp> Multicentre Cohort Study
Alimentary Pharmacology & Therapeutics 2025cited by 11position: middledoi
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
˜The œLancet. Gastroenterology & hepatology 2023cited by 105position: middledoi
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID
Journal of Crohn s and Colitis 2023cited by 19position: middledoi
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study
Inflammatory Bowel Diseases 2022cited by 42position: middledoi
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
Digestive and Liver Disease 2022cited by 32position: middledoi
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus
Digestive and Liver Disease 2021cited by 32position: middledoi
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study
Alimentary Pharmacology & Therapeutics 2020cited by 82position: middledoi
Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study
Journal of Crohn s and Colitis 2020cited by 70position: middledoi
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease
Journal of Crohn s and Colitis 2020cited by 31position: middledoi
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study
Journal of Crohn s and Colitis 2020cited by 24position: middledoi
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study
Journal of Crohn s and Colitis 2019cited by 56position: middledoi
Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis
Scandinavian Journal of Gastroenterology 2018cited by 20position: middledoi
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
Gut 2017cited by 329position: middledoi
Development of the IBD Disk
Inflammatory Bowel Diseases 2017cited by 127position: middledoi
Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology 2017cited by 75position: middledoi
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology 2016cited by 191position: middledoi
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results
Journal of Crohn s and Colitis 2016cited by 41position: middledoi
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
The American Journal of Gastroenterology 2015cited by 1,820position: middledoi
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures
Clinical Gastroenterology and Hepatology 2015cited by 101position: middledoi
A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohnʼs Disease
Inflammatory Bowel Diseases 2014cited by 74position: middledoi
Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease
Clinical Gastroenterology and Hepatology 2013cited by 298position: firstdoi
Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease
Clinical Gastroenterology and Hepatology 2013cited by 135position: firstdoi
Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis
Inflammatory Bowel Diseases 2013cited by 72position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Laurent Peyrin‐Biroulet · Hôpital Lapeyronie9 papers (2013–2025)Mathurin Fuméry · Centre Hospitalier Universitaire Amiens-Picardie7 papers (2015–2025)Romain Altwegg · Centre Occitanie-Montpellier7 papers (2015–2025)Stéphane Nancey · Université Claude Bernard Lyon 17 papers (2015–2025)Xavier Roblin · Université Claude Bernard Lyon 15 papers (2015–2022)David Laharie · Clinical Investigation Center Plurithematic Tours5 papers (2017–2025)Aurélien Amiot · Friedrich-Alexander-Universität Erlangen-Nürnberg5 papers (2015–2025)Anthony Buisson · Centre Hospitalier Universitaire de Clermont-Ferrand4 papers (2015–2025)Barrett G. Levesque · Gilead Sciences (United States)4 papers (2013–2014) · 4 papers (2015–2020) · 4 papers (2019–2025)Cyrielle Gilletta · Hôpital des Enfants4 papers (2020–2025) · 4 papers (2015–2022) · 4 papers (2015–2018) · 4 papers (2019–2022)William J. Sandborn · Mirati Therapeutics (United States)4 papers (2013–2014) · 4 papers (2015–2020) · 3 papers (2017–2025)Guillaume Pineton de Chambrun · Centre Hospitalier Universitaire de Montpellier3 papers (2015–2022)Guillaume Cadiot · Institut de Recherche en Santé Digestive3 papers (2016–2020)